Curated News
By: NewsRamp Editorial Staff
September 23, 2026
Helus Pharma Shareholders Approve Name Change and Board
TLDR
- Helus Pharma's name change and Phase 3 asset HLP003 with FDA Breakthrough Therapy Designation position it as a leader in mental health therapeutics.
- Shareholders approved auditor, eight directors, and the legal name change from Cybin Inc. to Helus Pharma Inc., effective October 1.
- Helus Pharma advances novel serotonergic agonists to provide durable improvements for people suffering from depression, anxiety, and other mental health conditions.
- Helus Pharma, formerly Cybin, is developing proprietary NSAs that activate serotonin pathways to promote neuroplasticity and heal minds.
Impact - Why it Matters
The approval of the legal name change from Cybin Inc. to Helus Pharma Inc. marks a pivotal moment for the company as it transitions from a clinical-stage discovery firm to a commercial-ready pharmaceutical entity. This shift is significant for investors and patients alike, as it signals the company’s confidence in its pipeline of novel serotonergic agonists (NSAs) targeting depression and anxiety. With HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, Helus Pharma is positioning itself to address a massive unmet need in mental health. The Breakthrough Therapy Designation for HLP003 from the FDA underscores the potential of its approach. As mental health disorders affect millions worldwide, the success of Helus Pharma’s NSAs could revolutionize treatment options, offering new hope for patients who have not responded to existing therapies. Moreover, the company’s global operations across Canada, the U.S., the U.K., and Ireland highlight its ambition to become a leader in the neuropsychiatric space. For investors, the rebranding and corporate restructuring may enhance visibility and attract new capital, driving further development. Ultimately, this news matters because it represents a step forward in the fight against mental illness, with the potential to improve lives and create significant shareholder value.
Summary
Helus Pharma, the commercial operating name of Cybin Inc., announced voting results from its annual and special meeting of shareholders held on September 22, 2026. Shareholders representing 46,452,598 common shares, or 63.58% of outstanding shares, appointed Zeifmans LLP as auditor, approved an eight-member board, and elected directors Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall, and Eric So. Additionally, shareholders approved changing the company’s legal name from Cybin Inc. to Helus Pharma Inc., effective October 1, following the adoption of the Helus Pharma business name on January 5. This rebranding reflects the company’s anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. For full details, visit the press release at https://nnw.fm/H4DVg.
Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Its NSAs target the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. It is also developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. With an extensive research portfolio of investigational NSAs, Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram.
The latest news and updates relating to HELP are available in the company’s newsroom at https://nnw.fm/HELP. This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Shareholders Approve Name Change and Board
